| Identification | Back Directory | [Name]
HA 130 | [CAS]
1229652-21-4 | [Synonyms]
HA 130
HA 150
CS-1606
HA130 (HA-130)
HA130;HA-130;HA 130
HA130 (Autotaxin Inhibitor)
(Z)-3-((4-((3-(4-fluorobenzyl)-2,4-dioxothiazolidin-5-ylidene)methyl)phenoxy)methyl)phenylboronic acid
B-[3-[[4-[[3-[(4-Fluorophenyl)Methyl]-2,4-dioxo-5-thiazolidinylidene]Methyl]phenoxy]Methyl]phenyl]boronic Acid
Boronic acid, B-[3-[[4-[[3-[(4-fluorophenyl)methyl]-2,4-dioxo-5-thiazolidinylidene]methyl]phenoxy]methyl]phenyl]- | [Molecular Formula]
C24H19BFNO5S | [MDL Number]
MFCD20926343 | [MOL File]
1229652-21-4.mol | [Molecular Weight]
463.29 |
| Chemical Properties | Back Directory | [storage temp. ]
Store at -20°C | [solubility ]
DMF:10.0(Max Conc. mg/mL);21.58(Max Conc. mM)
DMSO:30.11(Max Conc. mg/mL);64.99(Max Conc. mM)
Ethanol:0.5(Max Conc. mg/mL);1.08(Max Conc. mM) | [form ]
Powder | [color ]
Light yellow to yellow |
| Hazard Information | Back Directory | [Uses]
HA 150 is a selective boronic acid-based inhibitor of autotaxin. Studies show that adminstration of HA 150 in mice results in rapid decrease of the lipid mediator lysophosphatidic acid (LPA) in the circulation. These findings suggest that HA 150 may provide useful therapeutic strategy in treating disorders associated with vascular development, inflammation, fibrotic disease, and tumor progression. | [in vivo]
HA130 slows T cell migration across lymph node HEVs. HA130 decreases the "outside HEVs/inside HEVs" ratio by 3-4-fold compared to vehicle-treated animals vehicle[1].
The s.c. administration of HA130 induces marked lymphocyte accumulation within the endothelial cell (EC) and sub-EC layers of HEVs in draining lymph nodes (LNs)[2]. | [IC 50]
Autotaxin: 28 nM (IC50) | [storage]
Store at -20°C |
|
|